GWPH - GWPH Stock Slumps Despite Solid Q3 Earnings Thanks to Epidiolex

GWPH stock is having its worst one-day fall in the past few months despite GW Pharmaceuticals (NASDAQ:GWPH) posting better-than-expected revenue from its flagship product, Epidiolex.

Despite the troubles of the past few months, some companies in the cannabis industry have managed to perform well in the third quarter, and the latest company to exceed expectations is GW Pharmaceuticals. GW Pharmaceuticals is involved in producing medicines derived from CBD, and its most important product is Epidiolex, a CBD-infused medicine meant for epilepsy.

In its Q3 2019, the company managed to surpass expectations with ...